These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21856040)

  • 1. Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients.
    Wan J; Abuabara K; Troxel AB; Shin DB; Van Voorhees AS; Bebo BF; Krueger GG; Callis Duffin K; Gelfand JM
    J Am Acad Dermatol; 2012 Mar; 66(3):376-86. PubMed ID: 21856040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.
    Gelfand JM; Wan J; Callis Duffin K; Krueger GG; Kalb RE; Weisman JD; Sperber BR; Stierstorfer MB; Brod BA; Schleicher SM; Bebo BF; Troxel AB; Shin DB; Steinemann JM; Goldfarb J; Yeung H; Van Voorhees AS
    Arch Dermatol; 2012 Apr; 148(4):487-94. PubMed ID: 22508874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis.
    Abuabara K; Wan J; Troxel AB; Shin DB; Van Voorhees AS; Bebo BF; Krueger GG; Callis Duffin K; Gelfand JM
    J Am Acad Dermatol; 2013 Feb; 68(2):262-9. PubMed ID: 22910105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.
    Yeung H; Wan J; Van Voorhees AS; Callis Duffin K; Krueger GG; Kalb RE; Weisman JD; Sperber BR; Brod BA; Schleicher SM; Bebo BF; Shin DB; Troxel AB; Gelfand JM
    J Am Acad Dermatol; 2013 Jan; 68(1):64-72. PubMed ID: 22846688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.
    Takeshita J; Wang S; Shin DB; Callis Duffin K; Krueger GG; Kalb RE; Weisman JD; Sperber BR; Stierstorfer MB; Brod BA; Schleicher SM; Robertson AD; Linn KA; Shinohara RT; Troxel AB; Van Voorhees AS; Gelfand JM
    J Am Acad Dermatol; 2014 Dec; 71(6):1167-75. PubMed ID: 25260564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis.
    Wan J; Abuabara K; Troxel AB; Shin DB; Van Voorhees AS; Bebo BF; Krueger GG; Callis Duffin K; Gelfand JM
    Arch Dermatol; 2012 Apr; 148(4):539-41. PubMed ID: 22508884
    [No Abstract]   [Full Text] [Related]  

  • 7. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
    Strober BE; Poulin Y; Kerdel FA; Langley RG; Gu Y; Gupta SR; Okun MM; Papp KA
    J Am Acad Dermatol; 2011 Apr; 64(4):671-81. PubMed ID: 21414495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy.
    Strober BE; Poulin Y; Teller C; Wang Y; Williams DA; Goldblum OM
    J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1701-6. PubMed ID: 24422992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermatologists' views and opinions about photo(chemo)therapy and conventional systemic psoriasis therapies: results from a Belgian survey.
    Nijsten T; Lambert J
    Dermatology; 2006; 213(2):123-33. PubMed ID: 16902289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
    Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
    J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis].
    Vañó-Galván S; Gárate MT; Fleta-Asín B; Hidalgo A; Fernández-Guarino M; Bermejo T; Jaén P
    Actas Dermosifiliogr; 2012 Mar; 103(2):127-37. PubMed ID: 22036021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation.
    Grozdev IS; Van Voorhees AS; Gottlieb AB; Hsu S; Lebwohl MG; Bebo BF; Korman NJ;
    J Am Acad Dermatol; 2011 Sep; 65(3):537-545. PubMed ID: 21496950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients.
    Park KK; Wu JJ; Koo J
    J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):899-906. PubMed ID: 22702846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
    Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.